Table 6 Comparison with previous studies.

From: Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

Parameters PLAGH Phase II Trial Phase III Trial
850 mg QD 425 mg BID 850 mg QD
No. of patients 36 47 46 176
Survival
 median OS (months) 5.8 4.83 4.27 6.5
  95% CI 4.77–6.83 4.03–5.97 3.83–4.77 4.8–7.6
 median PFS (months) 2.65 3.67 3.2 2.6
  95% CI 1.66–3.54 2.17–6.80 2.37–4.53 2.0–2.9
Responses
 ORR 5.56% 6.38% 13.04% 2.84%
 DCR 58.33% 51.06% 34.78% 42.05%
Adverse events
 Hypertension Grade ≥ 1 38.90% 40.43% 39.13% 35.20%
Grade ≥ 3 2.80% 8.51% 10.87% 4.50%
 Proteinuria Grade ≥ 1 36.10% 27.66% 34.78% 47.70%
Grade ≥ 3 2.80% 2.13% 4.35% 2.30%
 Hand-foot syndrome Grade ≥ 1 19.40% 25.53% 45.65% 27.80%
Grade ≥ 3 8.30% 4.26% 13.04% 8.50%
  1. (Survival and response data in Phase II Trial were from intent-to-treat (ITT) patients. In Phase III Trial, survival data were from the full analysis set (FAS) patients, and response data were assessed by investigators).